Apmis最新文献

Forssman was a Swedish pathologist and microbiologist who, in the 1920s and 1930s conducted a long series of experiments that led to unique insights into surface antigens of blood cells, as well as added to the discrimination of toxins produced by staphylococci that lyse red blood cells. This review takes offset in the studies published by Forssman in APMIS addressing the hemolytic properties of staphylococcal toxins displayed against erythrocytes of animal and human origin. In light of current knowledge, we will discuss the insights we now have and how they may pave the way for curing infections with pathogenic staphylococci, including Staphylococcus aureus.

This study aimed to identify laboratory factors predicting leprosy relapse (LR) after multi-drug therapy (MDT). A case-control study included 80 patients treated with MDT at a national reference center over 12 years. The Relapse Group had 40 patients who relapsed after an average of 89.2 months post-MDT, while the Control Group had 40 patients who remained asymptomatic for an average of 113.1 months. Significant predictors of LR included neural/perineural lymphocytic infiltrate (OR = 4.67; p = 0.0076) and foamy granulomas (OR = 15.55; p = 0.0005), increasing odds by 4.7 and 15.6 times, respectively. The Relapse Group had a mean histological bacillary index (hBI) of 3.23+ compared to 1.8 in the Control Group (p = 0.004). An hBI ≥3+ had 72% sensitivity and 65% specificity for detecting LR (AUC = 0.72; p = 0.0002). Elevated anti-phenolic glycolipid I (anti-PGL-I) IgM antibody levels (ELISA index, EI ≥1) were also associated with LR (OR = 4.67; p = 0.0031). An EI ≥3.6 had 71% sensitivity and 62% specificity (AUC = 0.70; p = 0.0012). Multivariate analysis indicated that neural/perineural infiltrate, foamy granulomas, hBI ≥ 1+, and EI ≥ 1 significantly predicted LR, with up to 94.32% probability. Conclusively, these factors can identify individuals at high probability of LR after MDT.

The Gram-negative bacterium Klebsiella pneumoniae (K. pneumoniae) is one major causative agent of community- and hospital-acquired pneumonia. Echinacoside (ECH) is a phenylethanoid glycoside isolated from Cistanche deserticola that possesses anti-inflammatory activity. Our research aimed to confirm whether ECH alleviates K. pneumoniae-induced pneumonia and explore the underlying regulatory mechanisms. BEAS-2B cells and BALB/c mice were infected by K. pneumoniae to establish the cellular and animal models, respectively, followed by ECH treatment. Inflammatory cytokine levels were detected by RT-qPCR and ELISA. The lung wet/dry (W/D) weight ratio and the myeloperoxidase (MPO) activity in lung tissues were examined. The pulmonary histopathologic changes were observed through hematoxylin and eosin (H&E) staining. The levels of TLR4/NF-κB pathway-associated molecules were estimated through western blotting, immunohistochemical, and immunohistochemical staining. K. pneumoniae infection caused lung histopathologic damage, enhanced MPO activity, elevated lung W/D weight ratio, and upregulated inflammatory cytokine levels in mice and promoted inflammatory cytokine expression in BEAS-2B cells, which were reversed by ECH treatment. K. pneumoniae infection-induced upregulation in TLR4, phosphorylated (p)-p65, and p-IκBα levels, and downregulation in IκBα levels in BEAS-2B cells and pneumonia mice were overturned by ECH treatment. ECH ameliorates K. pneumoniae-induced pneumonia through suppressing the TLR4/NF-κB pathway.

This study prospectively collected the clinical data, information on respiratory pathogens, and laboratory findings of children with Mycoplasma pneumoniae (M. pneumonia) infection who were hospitalized at the First Affiliated Hospital of Anhui Medical University during the M. pneumoniae outbreak in Hefei City, Anhui Province, China, between October 2023 and December 2023. We analyzed the prevalence of M. pneumoniae infection in hospitalized children during the M. pneumoniae outbreak, discrepancies in the detection of M. pneumoniae by multiplex polymerase chain reaction (PCR) and serological methods, and the differences in clinical characteristics and laboratory results of patients with co-infections of M. pneumoniae and other pathogens with the aim of providing a reference for disease assessment and clinical treatment of M. pneumoniae. A total of 270 children, 146 males and 124 females, were enrolled in the study after screening with the inclusion criteria. The most common co-infections were adenovirus (ADV) (48 cases) and influenza A virus (FLU A) (30 cases). The prevalence of infections was higher in children under the age of 7 years (54.1%). In addition, 167 of the PCR-positive patients were infected with macrolide-resistant Mycoplasma pneumoniae (MRMP), suggesting that MRMP infections are common in hospitalized children. Levels of procalcitonin (PCT) (OR 15.765 [95% CI, 1.651-150.533], p < 0.017) and lactate dehydrogenase (LDH) (OR 1.006 [95% CI, 1.003-1.009], p < 0.001) were independently predictive of co-infections in patients infected with M. pneumoniae.

Fritz Kauffmann (1899-1978) was a German/Danish microbiologist, who worked most of his years studying intestinal bacteria at Statens Serum Institut in Denmark. During his research, he implemented several diagnostic tools, which are still used in reference laboratories worldwide. Kauffmann was probably most known for developing the "Kauffmann-White scheme" based on the O- and flagella antigens on the surface of Salmonella. He was a visionary in his field, working at the intersection of microbiology and public health, as his research enabled proper diagnosis and tracking of diseases around the world.

Development of antibodies for clinical use is a complex process involving numerous aspects, with antigen specificity being the most important. Initially, polyclonal antibodies, that can recognize multiple specific and nonspecific antigens (polyreactive), were developed and were very effective in the treatments. Later on, the polyspecificity/polyreactivity of these polyclonal antibodies (binding to multiple antigens) raised concerns about therapeutic efficacy because of their nonspecific interactions and challenges, such as development of immune complexes, batch-to-batch variability. This highlighted the need for more targeted approaches. It was resolved by the marked invention of hybridoma technology in 1975 which resulted in the revolution in the antibody development field by offering monoclonal monospecific antibodies (bind single antigen). However, their limited application in complex pathologies sparked a paradigm shift, leading to the resurgence of polyspecific antibodies in the form of monoclonal polyspecific antibodies (Polybodies), which bind multiple antigens, but specifically. Till today, 14 Polybodies are approved for clinical use. This fluctuation in antigen specificity is directing the evolution of engineered antibodies that are going to drive the biopharmaceutical sector in the coming years. Through this write-up, we assert the fluctuating nature of antigen specificity during the antibody development and how it will be crucial for advancing biologics.

The Swedish scientist Örjan Ouchterlony published four ground-breaking papers 1948-1966 in Acta Pathol Microbiol Scand where he described a new method of antigen-antibody reactions in gel. He described and defined the 'reaction of identity' and 'reaction of partial identity' when he used related antigens and 'reaction of non-identity' when he used non-related antigens. His results inspired scientists in other countries to further develop and modify the 'Ouchterlony method' which became useful for both scientific and clinical purposes. This survey describes how the methods were discovered and how they became modified and improved and how they were used, but also underlines that the original Ouchterlony method is still used.

Infections of intact and damaged skin barriers and keratin are frequently associated with complex biofilm communities containing bacteria and fungi, yet there are limited options for successful management. This study intended to focus on the utility of some novel proprietary lactam molecules, quorum sensing (QS)-derived halogenated furanones, which act to block the QS pathway, against key fungal pathogens of the skin (Candida albicans, Malassezia furfur and Microsporum gypseum). Moreover, we aimed to assess how these actives performed against complex interkingdom biofilms in a clinically relevant model. Two lactam derivatives were tested against a panel of important fungal pathogens and then quantitatively assessed against simple and increasingly complex interkingdom biofilm models on polystyrene coverslips and a novel keratin hydrogel system. The lactams were shown to be effective against a wide range of fungal species in the planktonic and biofilm forms, with no ability to regrow. The fungal component of the multispecies biofilm models was significantly reduced with lactam treatment. Lactam treatment was also comparably effective compared to the non-prescription topical antifungal 'Lamisil' against C. albicans early and late biofilms. This study highlights the effectiveness of lactams as a novel antimicrobial for the management of the polymicrobial and interkingdom multispecies biofilms.

This manuscript commemorates the 100th anniversary of APMIS, highlighting its evolution from a regional journal, founded in 1924 as Acta Pathologica et Microbiologica Scandinavica, to an international platform fostering global collaboration in pathology, microbiology, and immunology. The journal's inception was driven by Ulrik Quensel's vision in 1919, leading to the establishment of the Northern Pathological Society and the launch of the journal in 1924. APMIS has consistently published landmark research, including significant contributions from prominent. These studies have advanced understanding in fields such as pathology, microbiology, and immunology. The journal expanded its scope in the 1970s to include immunology, rebranding as APMIS in the mid-1980s. Recent decades have seen a continued commitment to cutting-edge research and an increasing impact factor. As APMIS transitions to an Open Access model under Wiley, it will be renamed the PMI Journal (Pathology, Microbiology, and Immunology) to reflect its global reach and dedication to scientific excellence. This centennial celebration acknowledges the contributions of editors, authors, and readers, looking forward to future advancements in biomedical research.

Type 1 diabetes (T1D) is an autoimmune disease, resulting in diminished islet integrity and destruction of the insulin-secreting beta cells. In this review, we investigate the intrinsic relationship between the development of T1D and the activity of the beta cells. The idea was initially hypothesized in 1982 that an increased beta-cell activity would enhance the surface antigen expression and thereby attract the immune system. Later, other findings support this idea, including increased risk of T1D development during third trimester of pregnancy, and the difference in T1D incidence in Russian and Finnish Karelia due to different lifestyles. Other implications of high beta-cell activity, such as reduced sulfatide levels, formation of non-correct insulin molecules and an increase in IFN-alpha upon virus attack, can contribute to the development of T1D. A possible way to prevent the development of T1D is to diminish beta-cell activity, which has shown promising results in animal models.